WCLC 2021 | BFAST: High dose alectinib for RET-positive NSCLC

Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the safety and efficacy results of high-dose alectinib treatment for patients with treatment naïve RET-positive non-small cell lung cancer in the Blood First Assay Screening Trial (BFAST). BFAST (NCT03178552) is an ongoing study of targeted treatment/immunotherapy in treatment-naïve NSCLC, determined by the genomic features of a participant’s cell-free DNA. The RET cohort underwent Phase I dose-escalation with alectinib at a higher dose than is used as standard. While the study demonstrated tolerability of high dose alectinib, low response rates led to premature closure of Phase I enrollment, and Phase II was not started. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.